New Hope for Gestational Diabetes: Gates Foundation-Backed Research Targets Postpartum Risk

Could a new oral therapy help protect new mothers from developing type 2 diabetes after pregnancy? A groundbreaking initiative from Cirius Therapeutics says yes — and the Gates Foundation agrees.

Gestational diabetes is one of the most common pregnancy complications in the world — and one of the most underestimated. While it typically resolves after delivery, the long-term health consequences for mothers can be severe. Now, a Michigan-based biotech company has secured a Gates Foundation planning grant to develop the first postpartum treatment specifically targeting women who develop gestational diabetes mellitus (GDM) — and the results could reshape how we approach maternal metabolic health worldwide.

What Is Gestational Diabetes and Why Does It Matter After Delivery?

Gestational diabetes mellitus (GDM) is a form of high blood sugar that develops during pregnancy, typically in the second or third trimester. It occurs when the body cannot produce enough insulin to meet the increased demands of pregnancy.

Most women are screened between weeks 24 and 28 of pregnancy using a glucose challenge test or glucose tolerance test. For many, the condition resolves shortly after delivery — but the story doesn't end there.

What many women don't realize is that having GDM significantly raises their lifetime risk of type 2 diabetes and other serious metabolic diseases. That postpartum window — especially the first year after delivery — is a critical and often missed opportunity for intervention.

GDM by the Numbers: A Global Health Challenge

The scale of gestational diabetes is hard to overstate:

• GDM affects an estimated 10–20% of pregnancies worldwide

• It occurs across all demographics, in both high-income and low- and middle-income countries (LMICs)

• Women with a history of GDM face substantially elevated risks of developing type 2 diabetes, kidney disease, and cardiometabolic complications — often within the first year postpartum

• In LMICs, postpartum screening and treatment options are frequently limited or unavailable entirely

Despite these risks, there are currently no approved therapies specifically designed for postpartum use in women who have had GDM. That gap is exactly what Cirius Therapeutics is working to close.

Cirius Therapeutics Announces Gates Foundation-Backed GDM Initiative

On April 28, 2026, Cirius Therapeutics, Inc. — a Grand Rapids, Michigan-based clinical-stage pharmaceutical company — announced a planning grant from the Bill & Melinda Gates Foundation to advance development of its investigational compound CIR‑0602K as a potential postpartum therapy for women with a history of gestational diabetes.

The grant funds an initial planning and preparation phase focused on:

• Examining potential exposure of CIR-0602K in breast milk

• Building the scientific evidence base needed to responsibly advance toward clinical studies

• Enabling future trials in women immediately postpartum, subject to regulatory feedback

• Designing studies relevant to both high-income countries and LMICs

As Cirius CEO Dr. Robert Beardsley explained: the initiative reflects a shared commitment to improving cardiometabolic health for new mothers who face serious long-term risk but currently have very few options.

What Is CIR-0602K?

CIR-0602K is an orally administered mitochondrial pyruvate carrier (MPC) inhibitor — a novel type of metabolic therapy that works by reprogramming how the body's cells produce and use energy at the mitochondrial level.

Here's why that matters for gestational diabetes and its aftermath:

Insulin resistance — the underlying driver of both GDM and type 2 diabetes — is rooted in mitochondrial dysfunction. By selectively inhibiting the MPC protein, CIR-0602K targets this dysfunction directly, reducing insulin resistance in cells and supporting healthier metabolic function throughout the body.

The compound has already completed seven U.S. clinical trials, including:

• A 52-week Phase 2b study in 392 participants with metabolic-associated steatohepatitis (MASH), with and without type 2 diabetes

• A 28-day Phase 2a study in 129 participants with type 2 diabetes

• A pilot study showing marked reductions in HbA1c, insulin levels, and fat in muscle in people with obesity and type 2 diabetes

Across those studies, CIR-0602K has demonstrated reductions in HbA1c and insulin levels, improvements in liver function, and benefits even in patients already on GLP-1 therapies like semaglutide or tirzepatide.

If future studies confirm its safety and efficacy postpartum, CIR-0602K could offer a practical, once-daily oral option to reduce the progression from GDM to type 2 diabetes, kidney disease, and other chronic conditions.

The Role of Certara and the Simcyp® Simulator

One of the most critical questions in any postpartum therapy study is safety for breastfeeding infants. Studying drug exposure in nursing mothers and their babies is both ethically complex and historically underrepresented in clinical research.

To address this, Cirius is partnering with Certara — a global leader in model-informed drug development — and its Simcyp® Simulator to predict drug exposure in breastfeeding mothers and infants using sophisticated computational modeling. This allows researchers to anticipate pharmacokinetic data before exposing real participants, enabling a more responsible, stepwise path to clinical evaluation.

According to Karen R. Yeo, Senior Vice President at Certara, this approach is structured to first build the evidence base needed before moving toward clinical evaluation — with the ultimate objective of informing postpartum care on a global scale.

Why This Matters for Women With a History of Gestational Diabetes

If you have experienced gestational diabetes, here is what current science tells us about your health outlook — and why this research is so important:

Your risk of type 2 diabetes is significantly elevated. Studies suggest that women with GDM have up to a 10-fold higher lifetime risk of developing type 2 diabetes compared to women who did not have GDM. That risk is highest in the first 5 years postpartum.

The postpartum period is often when care falls through the cracks. After delivery, the focus understandably shifts to the baby. Many women miss their 6-week postpartum glucose screening. Long-term metabolic monitoring is even less common.

Lifestyle changes help, but may not be enough. Diet and exercise after GDM can reduce — but not eliminate — the risk of type 2 diabetes. An effective pharmacological option could be a crucial complement to lifestyle interventions.

Access is a global equity issue. In low- and middle-income countries, where rates of GDM are high but resources are limited, an affordable oral therapy could be transformative.

What You Can Do Right Now

While CIR-0602K is still in development and not yet available to patients, there are evidence-based steps women with a history of GDM can take today:

1. Get screened postpartum. The American Diabetes Association recommends a 75g oral glucose tolerance test (OGTT) 4–12 weeks after delivery, and repeat testing every 1–3 years thereafter.

2. Talk to your doctor about your GDM history. Make sure every healthcare provider you see knows about your GDM — including primary care, OB/GYN, and any specialists.

3. Prioritize blood sugar-friendly nutrition. A diet lower in refined carbohydrates and higher in fiber, lean proteins, and healthy fats can meaningfully reduce progression risk.

4. Stay active. Regular physical activity — even 150 minutes of moderate walking per week — significantly improves insulin sensitivity.

5. Track your weight. Returning to a healthy weight after delivery is one of the strongest modifiable risk factors for preventing type 2 diabetes after GDM.

The Bottom Line

Gestational diabetes isn't just a pregnancy complication — it's a warning signal for lifelong metabolic health. For too long, the postpartum period has represented a missed opportunity to intervene before type 2 diabetes takes hold.

The Cirius Therapeutics initiative, backed by the Gates Foundation, is a meaningful step toward filling that gap — not just in wealthy countries, but globally. With a well-characterized compound, a rigorous scientific partnership with Certara, and a commitment to access in low-income settings, this program has the hallmarks of research that could genuinely change outcomes for millions of women.

We'll continue covering the progress of CIR-0602K and other emerging gestational diabetes therapies here at DirectDiabetes.com. Bookmark this page and sign up for our newsletter to stay informed.

This article is for informational purposes only and does not constitute medical advice. If you have a history of gestational diabetes or concerns about your diabetes risk, please consult your healthcare provider.